matchedPattern,context,lineNumber,columnNumber,publicationName
p.L1341P,...or our experimental design: DYSF p.G299R and DYSF p.L1341P. The consequences of these mutations at t...,18,100,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...r missense-mutated dysferlin cDNA DYSF p.G299R or p.L1341P. Transfected cells were treated with TAT-...,21,134,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...r but not expressed at the sarcolemma. (G–I) DYSF p.L1341P-GFP tagged. Experiment performed 12×. (G)...,21,786,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...ed. (H) Peptide B2 (10-mer) corresponding to DYSF p.L1341P supports reallocation of dysferlin to the...,21,902,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...ma. (I) Peptide B4 (15-mer) corresponding to DYSF p.L1341P. 10mer peptides carrying the correspondin...,21,1011,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...obtained from patients with DYSF p.G299R and DYSF p.L1341P. Missense mutated dysferlin accumulates w...,39,161,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...y human myotubes harboring the dysferlin mutation p.L1341P. Experiment performed 7x. (D) No peptides...,42,724,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...) Peptide B2 (10-mer) added corresponding to DYSF p.L1341P. (F) Sarcolemmal dysferlin localization i...,42,834,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,"... normal and dysferlin-mutant human myotubes. DYSF p.L1341P myotubes, untreated and treated with TAT-...",50,209,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,"... hardly detectable and closes rapidly. (D–F) DYSF p.L1341P primary human myotube 6, 20 and 90 sec af...",53,355,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...lesion continuously increases in size. (G–I) DYSF p.L1341P primary human myotube treated with corres...,53,473,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,"...otubes. Peptide B2, which corresponds to the DYSF p.L1341P mutation, was fluorescently labeled with ...",56,174,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...t C2E domain of dysferlin that contained the DYSF p.L1341P mutation and the corresponding wildtype o...,56,845,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,Peptide B2 corresponding to DYSF p.L1341P was labeled with ATTO-495-ME fluorescent ...,59,34,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...TO-495-ME fluorescent dye (red) and added to DYSF p.L1341P human myotubes. (A) DYSF p.L1341P human m...,59,112,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...d added to DYSF p.L1341P human myotubes. (A) DYSF p.L1341P human myotube immediately after addition ...,59,146,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,"... after addition of ATTO-495-ME-peptide B2 to DYSF p.L1341P human myotubes, (B) after 8 minutes and (...",59,230,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...895G>A; p.G299R; homozygosity for DYSF c.4022T>C; p.L1341P. Muscle specimens were placed in 30.2 mM ...,91,506,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...man muscle cells endogenously expressing the DYSF p.L1341P mutation [52],91,1354,PLoS_One_2012_Nov_20_7(11)_e49603.txt
p.L1341P,...lin and dysferlin mutations DYSF p.G299R and DYSF p.L1341P 10 and 15mer peptides were synthesized an...,94,83,PLoS_One_2012_Nov_20_7(11)_e49603.txt
